Market Access News | pharmaphorum

News

Lilly names Pennsylvania site for its latest US facility

Eli Lilly has revealed the fourth new manufacturing site in its $27 billion capital investment spree in the US - a $3.5bn facility in Pennsylvania.

News

Bottle of Tavneos with two pills in front of it

EMA looks into 'data integrity' issue with Amgen's Tavneos

Concerns about efficacy data in the main trial behind the approvals of Amgen and CSL Vifor's Tavneos have triggered a review in the EU.

News

FDA starts review of Summit's VEGFxPD-1 bispecific

Summit moves ahead in the race to bring a VEGFxPD-(L)1 drug to market, after the FDA started a review of ivonescimab in lung cancer.

News

Tenpoint eyes presbyopia drug launch after FDA nod

Tenpoint is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis, and LENZ with a dual-acting rival.

News

ADHD in wooden letters surrounded by white pills

Otsuka preps for July decision on centanafadine for ADHD

The FDA has started a priority review of Otsuka's triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

Lilly names Pennsylvania site for its latest US facility

EMA looks into 'data integrity' issue with Amgen's Tavneos

FDA starts review of Summit's VEGFxPD-1 bispecific

Tenpoint eyes presbyopia drug launch after FDA nod

Otsuka preps for July decision on centanafadine for ADHD

CMS's Medicare price negotiations start round three

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks